Iterum is developing sulopenem, a novel oral and intravenous penem antibiotic with broad-spectrum in‑vitro activity against Gram‑negative pathogens including ESBL mutants of E. coli and K. pneumoniae. The company holds QIDP designations for its oral and IV formulations for uUTI, cUTI and cIAI and is advancing a pivotal Phase 3 program. Iterum plans to use proceeds from the financing to complete a Phase 3 pivotal trial in uncomplicated UTI and to advance the broader Phase 3 program, with trials expected to begin in the first half of 2018. The company aims to file an NDA with the FDA by year‑end 2019. Iterum's leadership includes CEO Corey Fishman and CSO Michael Dunne, MD, and the team has prior antibiotic development experience. The company is backed by a blue‑chip venture syndicate and is focused on addressing multi‑drug resistant pathogens.

Total raised

$65M

Funding rounds

1

Latest round

Series B

Latest activity

May 2017